Sudden cardiac death (SCD) remains one of the most pressing global health problems. The United States National Young Athlete WBC Registry data show a progressive increase of SCD over the past 2.5 decades, averaging 6% per year. Despite this, there are no SCD statistics in the Republic of Kazakhstan. To study the early SCD predictors is one of the urgent tasks of modern healthcare. This review discusses the modern biomarker IL1RL1(ST2) used to diagnose SCD, myocardial fibrosis, and heart failure.